Effects of Constraint-Induced Movement Therapy on upper limb activity according to a bi-dimensional kinematic analysis in progressive multiple sclerosis patients: a randomized single-blind pilot study.

Effects of Constraint-Induced Movement Therapy on upper limb activity according to a bi-dimensional kinematic analysis in progressive multiple sclerosis patients: a randomized single-blind pilot study. Funct Neurol. 2019 Jul/Sep;34(3):151-157 Authors: de Sire A, Mauro A, Priano L, Baudo S, Bigoni M, Solaro C Abstract Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by demyelinization and axonal loss resulting, in 66% of cases, in upper limb motor impairment. The effects of constraint-induced movement therapy (CIMT) have recently been investigated in MS patients. The aim of this randomized single-blind pilot study was to assess the effects of CIMT on upper limb activity, specifically smoothness of movement, in patients affected by progressive MS. Patients affected by MS, and reporting reduced use primarily of one upper limb, were enrolled and randomly allocated to two different groups: a CIMT group, where treatment was performed with the less affected limb immobilized by a splint, and a control group, submitted to intensive bi-manual treatment. All evaluations were performed at baseline (T0) and after two weeks of treatment (T1) by an operator unaware of the patients' allocation. The primary outcome was the difference in movement smoothness, measured by means of a bidimensional kinematic evaluation. Secondary outcomes were: endpoint error and arm trajectory mean speed. Furthermore, patients performed the Hand Grip S...
Source: Functional Neurology - Category: Neurology Tags: Funct Neurol Source Type: research

Related Links:

Publication date: October 2020Source: Multiple Sclerosis and Related Disorders, Volume 45Author(s): Negar Ramezani, Pourya Yarahmadi, Mohammad Alirezaei, Seyed Mohammad Forouzannia, Razieh Sadat Kazemi Mozdabadi, Hossein Rezaei Aliabadi, Mohammad Reza Gheini, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Source: Patient Preference and Adherence - Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Authors: Wang Y, Bhargava P Abstract On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl fumarate (DMF), was approved for the same indication on March 27, 2013. Prior to its approval, DRF did not undergo rigorous testing to determine its efficacy, as its active metabolite, monomethyl fumarate, is the same as that of DMF (bioequivalency). The efficacy, safety and tolerability of DMF have previously been demonstrated in a number of clinical tria...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Publication date: October 2020Source: Multiple Sclerosis and Related Disorders, Volume 45Author(s): Juichi Fujimori, Kengo Uryu, Kazuo Fujihara, Mike P. Wattjes, Chihiro Suzuki, Ichiro Nakashima
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: October 2020Source: Pharmacological Research, Volume 160Author(s): Silvia Pontis, Francesca Palese, Maria Summa, Natalia Realini, Massimiliano Lanfranco, Claudia De Mei, Daniele Piomelli
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
AbstractThe proinflammatory cytokine interleukin 1 (IL-1) is crucially involved in the pathogenesis of multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Herein, we studied the role of IL-1 signaling in blood –brain barrier (BBB) endothelial cells (ECs), astrocytes and microglia for EAE development, using mice with the conditional deletion of its signaling receptor IL-1R1. We found that IL-1 signaling in microglia and astrocytes is redundant for the development of EAE, whereas the IL-1R1 deletion in BB B-ECs markedly ameliorated disease severity. IL-1 signaling in BBB-ECs up...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Conditions:   Relapsing Multiple Sclerosis;   Clinically Isolated Syndrome Intervention:   Drug: Ocrelizumab Sponsors:   University of California, San Francisco;   Genentech, Inc.;   Valhalla Charitable Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The quality of evidence that exists for occupational therapy with people with multiple sclerosis is mixed but there are studies that show that occupational therapy can improve occupational and other outcomes in this population. It is essential to build on the evidence that exists in the area. Implications for rehabilitation Occupational therapists are well-placed to intervene with multiple sclerosis symptoms. Evidence for the effectiveness of occupational therapy for people with multiple sclerosis is yet to be established. Fatigue management programmes delivered by occupational therapists are effective in reduc...
Source: Scandinavian Journal of Occupational Therapy - Category: Occupational Health Tags: Scand J Occup Ther Source Type: research
Publication date: Available online 10 July 2020Source: Brain, Behavior, and ImmunityAuthor(s): Giulia Magni, Silvia Pedretti, Matteo Audano, Donatella Caruso, Nico Mitro, Stefania Ceruti
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Patients with multiple sclerosis (MS) especially those with younger age experience an alteration in physiological and emotional lifestyle that can affect intimacy and sexuality. The aim of this study was to deter...
Source: Reproductive Health - Category: OBGYN Authors: Tags: Research Source Type: research
More News: Brain | Eyes | Multiple Sclerosis | Neurology | Statistics | Study